|
Oncology products: from the clinic to the patient
There can be no doubt that oncology drug development is entering a critical phase. However, developing Oncology products is full of major challenges that need to be met head on in order to bring safe and effective treatments to market.
|
For delegates
This US oncology event has been created from the success of its sister event Oncology Drug Development Europe.
This unique meeting will address the critical strategic, scientific and regulatory issues in the development of targeted oncology therapeutics.
This important meeting is for early to late stage development managers and directors working on oncology products.
» Take a look at last year's programme
» Reserve your seat now
|
All oncology experts in one place
|
|
Our speakers
At Oncology Drug Development USA you can expect to see speakers from a wide range of global countries. There will be case study updates, and we will strive to introduce fresh strategy content as we continue to keep track of the latest developments.
As is the Health Network ethos, we will continue to strive to make the conference a more interactive experience; meaning more workshops, panel sessions, debates and ultimately more audience involvement and networking opportunities.
» Enquire about becoming a speaker
» Reserve your seat now
|
For sponsors
This congress helps you overcome common business development hurdles, like access to the right people and face to face networking with the right people. Who will attend >
There are a limited number of opportunities for you to get your message across to the oncology industry, so act now to avoid disappointment. Our experienced team will help you to access the people that are most important for you to meet, generate new alliances, collaborations and define your brand as industry thought leaders.
» Find out how you could benefit
|
 Oncology speakers chosen for their expertise
Health Network is delighted to announce that a panel of the World’s most eminent drug development scientists, academics and strategists will be coming together to discuss the very latest challenges in bringing oncology products to market including:
- Finance: Dr Sapna Srivasta, Vice President, Morgan Stanley on the financial sectors expectation for the oncology marketplace
- Business development: Dr Brian Lovatt, Managing Director, CancerDeals on the value of cancer drugs in development
- Biomarker studies: Dr Hans Winkler, Senior Director, Translational Research, Johnson and Johnson on the utility and value of predictive response markers in oncology
- Early development: Dr Joe Montforte, VP and Chief Scientific Officer, Althea Technologies on achieving consistency of data from discovery to development
- Late stage clinical development: Dr Carlo Montagner, President, Abraxis Oncology on undertaking head to head clinical trials in phase IIB
Cutting edge presentations from industry leaders, breakout discussion and networking sessions, there can be no better way of staying abreast of the latest developments in oncology drug development.
» Looking for an event taking place sooner or in a different part of the world?
» Register online now
|
